These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6503980)

  • 1. [Thrombolytic agents].
    Furukawa K
    Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1166-9. PubMed ID: 6503980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thrombolytic treatment of deep venous thrombosis].
    Martínez-Brotons F; Cairols MA
    Sangre (Barc); 1984; 29(4-C):762-6. PubMed ID: 6515512
    [No Abstract]   [Full Text] [Related]  

  • 3. [Thrombolytic efficacy of a Lys-plasminogen-urokinase combination: studies in experimental animals and humans].
    Latorre J; Foncuberta J; Rosendo A; Elez J
    Angiologia; 1990; 42(6):218-26. PubMed ID: 2075946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Increased fibrinolytic activity by sequential treatment with defibrase-plasminogen-urokinase in pulmonary embolism and deep venous thrombosis].
    Brochier M; Griguer P; Raynaud P; Fauchier JP; Charbonnier B
    Arch Mal Coeur Vaiss; 1981 Jul; 74(7):761-9. PubMed ID: 6794497
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. Apropos of 67 cases].
    François G; Charbonnier B; Raynaud P; Garnier LF; Griguer P; Brochier M
    Arch Mal Coeur Vaiss; 1986 Apr; 79(4):435-42. PubMed ID: 3090961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does thrombolytic therapy have a place in the treatment of pulmonary embolism after the acute stage?
    Brochier M; Griguer P; Raynaud P; Charbonnier B; Desveaux B; François G
    Haemostasis; 1986; 16 Suppl 3():58-64. PubMed ID: 3770545
    [No Abstract]   [Full Text] [Related]  

  • 8. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the medical treatment of deep vein thrombosis.
    Schulman S
    Acta Med Scand Suppl; 1985; 704():1-68. PubMed ID: 3913282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental and clinical studies on oral urokinase and lysyl-plasminogen. Thrombolytic therapy for cerebral thrombosis].
    Naito I
    Rinsho Ketsueki; 1984 Jul; 25(7):1027-35. PubMed ID: 6389929
    [No Abstract]   [Full Text] [Related]  

  • 13. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral venous congestion as indication for thrombolytic treatment.
    Tsai FY; Kostanian V; Rivera M; Lee KW; Chen CC; Nguyen TH
    Cardiovasc Intervent Radiol; 2007; 30(4):675-87. PubMed ID: 17573553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
    Wojta J; Binder BR; Huber K; Hoover RL
    Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraarterial fibrinolysis: in vitro and prospective clinical evaluation of three thrombolytic agents.
    Pilger E; Lammer J; Bertuch H; Steiner H
    Radiology; 1986 Dec; 161(3):597-9. PubMed ID: 3786705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Do thrombolytic agents have a place in the treatment of pulmonary embolism after the acute phase?].
    Brochier M; Griguer P; Raynaud P; Charbonnier B; Desveaux B; François G; Garnier LF
    Haemostasis; 1986; 16 Suppl 4():62-8. PubMed ID: 3770558
    [No Abstract]   [Full Text] [Related]  

  • 19. [Multicentre clinical observation of anticoagulation and thrombolysis for the deep venous thrombosis].
    Wang HT; Jiang WL; Zhang YN; Sun ZF; Sun QF; Ma J
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(45):3181-5. PubMed ID: 20193529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thrombolytic therapy of deep venous thrombosis. Indications, treatment procedures].
    Theiss W
    Internist (Berl); 1992 Apr; 33(4):225-31. PubMed ID: 1612846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.